• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cansino Biolgics Reg H (OP:CASBF)

4.258 UNCHANGED
Streaming Delayed Price Updated: 11:12 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cansino Biolgics Reg H

News headline image
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗
August 12, 2023
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
News headline image
Why Is CanSino Biologics (CASBF) Stock Soaring Today? ↗
November 02, 2022
CanSino Biologics shares are ripping higher on Wednesday, with CASBF stock up more than 75%. The move comes as China pushes for more vaccines. 
Via InvestorPlace
News headline image
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal ↗
May 28, 2022
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and... 
Via Talk Markets
News headline image
Week In Review: Shanghai Regor To Discover Metabolic Therapies For Lilly In $1.55 Billion Deal ↗
December 11, 2021
Regor Therapeutics entered a $1.55 billion research pact with Eli & Lilly to discover therapies for metabolic disorders. Meanwhile, Beijing Avistone Pharma received a $200 million investment led by... 
Via Talk Markets
News headline image
Week In Review: Zai Lab Raises $750 Million In Private Placement For In-Licensed/Novel Drugs ↗
April 24, 2021
Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. It currently has a portfolio of 21 products. Zai has a market cap of $14 billion and over $1... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap